The companies developing new weight-loss medicines have a problem: the balance of power has shifted, and patients are bailing ...

James is a pulmonary and critical care physician specializing in sarcoidosis. When one of my patients was first diagnosed with sarcoidosis, her specialist gave her two options: take steroids or join a ...

Patients are not disengaging because they lack interest in research. They disengage when systems fail to connect.”— ...

Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), encourages biotech and pharmaceutical companies that are developing treatments and cures for ...

Participation in Electronic Patient-Reported Outcome Measures Collection as a Part of Routine Supportive Care Delivery in Oncology An electronic survey was administered to first-time telemedicine ...

The study will assess the tolerability, safety, maximum tolerated dose, and the recommended Phase II dose of PLT012.

Open communication in clinical trials helps prevent patients from feeling overwhelmed by complex details and enhances understanding. Initial discussions focus on general trial participation before ...

What happens to a patient after I refer them to a clinical trial? Do they leave my practice? Referring patients to a clinical trial is similar to referring them to a specialist. They remain your ...

After a freak accident left him blind and in agony, Phil Durst thought hope was lost. Then, a world-first stem cell trial changed everything.

DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence-based Clinical Trial Solutions for Patient Matching - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering ...

Rare Patient Voice is sharing new results from a survey conducted amongst their patient participant community on clinical trial co-design, to bring clarity to why and how the patient voice should be ...

The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...